August 16, 2016 - No Comments!

Omega Ophthalmics Receives Issuance of 1st Continuation Bravo Patent from USPTO

Lexington, KY – August 16, 2016

Omega Ophthalmics is pleased to announce that a continuation for Prosthetic Capsular Devices, Systems, and Methods has been issued by the United States Patent & Trademark Office (USPTO).

The patent for invention number 9,414,907 is for a “Prosthetic Capsular Devices, Systems, and Methods,” and contains protections surrounding "wearable technology that provides biometric data, such as blood glucose levels, body temperature, electrolyte balance, heart rate...and the like that can assist in technology-assisted health care functions."

Omega CMO Gary Wörtz notes that the issuance of the patent continuation is a crucial step in protecting future medical applications for Omega's prosthetic capsular bag.

"There are so many more potential applications for Omega's capsular bag than just intraocular lens insertion. From blood glucose monitoring technology to systems that can provide patients and physicians with biometric data, we believe that the eye is the perfect space to house such technology, and we're excited to enjoy such wonderful intellectual property protection in this area," says Wörtz.

This most recent continuation is for the second family of patents in Omega's portfolio. Originally filed in February 2012, Omega’s core patent was granted for “[helping] to maintain the volume of the natural capsular bag, thereby stabilizing the effective lens position of an IOL so that refractive outcomes may be improved with cataract surgery. The prosthetic capsular bag further provides an integrated refractive surface, providing a means for experimentally determining an effective lens position prior to inserting an IOL.”

Omega's other patent families have been issued in the United States, Canada, Australia, and Japan, and are accompanied by pending patents for the same technology in Australia, Europe, India, Japan, and several provisional United States and PCT patents.

Omega Ophthalmics has been conducting studies as part of the Food and Drug Administration (FDA) approval process for medical devices. Clinical animal studies has shown this capsular bag to be remarkably effective in helping maintain effective lens position as compared to other intraocular lenses, a critical component of cataracts surgery that determines whether or not a patient will need post-operative corrective lenses.

Cataract surgery is the single most common surgical procedure performed in the United States annually. With the global cataracts market currently projected to reach $4.3 billion by 2017, Omega’s capsular bag is well-positioned to become the new standard lens for cataract surgery.


Omega Ophthalmics is a medical device company making significant advancements in the global ophthalmology industry through its patent-pending, proprietary technologies for intraocular lenses, capsular bags, and high technology applications within the eye. Founded by Gary Wörtz, MD and Rick Ifland, Omega is headquartered in Lexington, KY.

For more information about Omega Ophthalmics, contact Rick Ifland, CEO.

For more information about Omega's technology, contact Gary Wörtz, MD, CMO.

Published by: Omega Ophthalmics in Company News, Intellectual Property, Press Releases

Leave a Reply